Drug company Roche made a rare foray into the markets recently, with BNP Paribas being among the bookrunners putting together its record-breaking euro bond deal to finance the purchase of US biotech firm Genentech. Writer Edward Russell-Walling
Drug company Roche made a rare foray into the markets recently, with BNP Paribas being among the bookrunners putting together its record-breaking euro bond deal to finance the purchase of US biotech firm Genentech. Writer Edward Russell-Walling